| Kathleen Welch, MD | |
|
5071 Hana Hwy, Haiku, HI 96708-5954 | |
| (808) 572-2113 | |
| (808) 572-2114 |
| Full Name | Kathleen Welch |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 5071 Hana Hwy, Haiku, Hawaii |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366615239 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 03502 (Hawaii) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kathleen Welch, MD 5071 Hana Hwy, Haiku, HI 96708-5954 Ph: () - | Kathleen Welch, MD 5071 Hana Hwy, Haiku, HI 96708-5954 Ph: (808) 572-2113 |
News Archive
At the 2009 Radiological Society of North America Annual Meeting (RSNA 2009), Canon U.S.A., Inc., a leader in medical imaging technologies, will celebrate the achievement of a Canon Inc. medical equipment manufacturing milestone as cumulative production of Canon CXDI Digital Radiography (DR) systems surpassed the 10,000 unit mark.
Like a bounty hunter returning escapees to custody, a cancer-fighting gene converts organ cells that change into highly mobile stem cells back to their original, stationary state, researchers report online at Nature Cell Biology.
Arisaph Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on discovery and development of novel therapies for cardiometabolic diseases and cancer, announced today that it has been awarded a phase II Small Business Technology Transfer (STTR) grant and a supplemental phase I grant, both from the National Cancer Institute of the National Institutes of Health.
Pearl Therapeutics Inc. today announced positive results from a randomized, double-blind, Phase 2b, dose-ranging study of its formoterol fumarate metered dose inhaler (FF MDI; PT005), a long-acting beta-2 agonist (LABA) compared to placebo and Foradil Aerolizer in patients with moderate-to-severe COPD.
A new study in American veterans posted to the medRxiv* preprint server suggests severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are less effective in preventing infection after six months. The decline was most significant with the Johnson & Johnson vaccine, with vaccine effectiveness plummeting from 88% to 3%.
› Verified 2 days ago
Dr. Barry Alan Sultanoff, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2401 Umi Pl, Haiku, HI 96708 Phone: 808-214-6449 |